Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Netscientific Plc LSE:NSCI London Ordinary Share GB00BN4R5Q82 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -1.72% 57.00 56.00 58.00 58.00 56.50 58.00 40,602 11:24:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.7 -3.6 -5.7 - 9

NetScientific PLC NetScientific acquires 100% of portfolio company

16/10/2020 7:00am

UK Regulatory (RNS & others)


Netscientific (LSE:NSCI)
Historical Stock Chart


From Sep 2020 to Oct 2020

Click Here for more Netscientific Charts.

TIDMNSCI

RNS Number : 2510C

NetScientific PLC

16 October 2020

NetScientific plc

("NetScientific" or the "Company")

NetScientific acquires 100% control of portfolio company ProAxsis Limited

London, UK - 16 October 2020 - NetScientific plc (AIM:NSCI), the life sciences and technology investment and commercialisation company, announces that it has agreed to acquire the outstanding minority interest of 43.6% of its portfolio company, ProAxsis Limited ("ProAxsis") from QUBIS Limited and the founders (the "Sellers"), for a cash consideration of GBP228,532.50. In parallel, the key patent has been assigned by the sellers.

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. This technology has been translated into a point-of-care test (NEATstik(R)), to enable ongoing monitoring of active NE levels.

In the year ended 31 December 2019, ProAxsis generated revenues of GBP734,842 and a loss after taxation for the financial year of GBP181,082, of which GBP52,178 was included with non-controlling interests. Its net liabilities as at 31 December 2019 amounted to GBP2,401,970, of which GBP1,045,577 was included with non-controlling interests. Following the acquisition, ProAxsis will be fully consolidated within the Group, with no amounts included with non-controlling interests, and operate as a separate subsidiary.

Dr. Ilian Iliev, Chief Executive Officer of NetScientific Plc said: "In line with the Group's Strategic Review and stated plans, ProAxsis is an example of the strong commercialisation potential of spin out companies from UK Universities such as Queen's University Belfast. This provides an early investment realisation opportunity for the company's two co-founders, Professor Lorraine Martin and Professor Brian Walker, while allowing the company to continue and accelerate its growth. In line with NetScientific's pro-active management, increasing our stake in ProAxsis via these agreements will enable us to provide the necessary support required to maximise the company's value and help the company capture synergies within our broader ecosystem in this growing sector. We are delighted that David Moore, the University's Head of Spin Outs and Investments at QUBIS, has agreed to remain on the ProAxsis board of directors for the foreseeable future."

For more information, please contact:

NetScientific

Ilian Iliev, CEO Tel: +44 (0)20 3514 1800

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel Tel: +44 (0)20 7220 1666

About NetScientific

NetScientific is a life sciences and technology investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value.

   For more information, please visit the website at:   www.NetScientific.net 

About ProAxsis

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.

This technology has been translated into a point-of-care test (NEATstik(R)), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik(R) enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

   For more information, please visit the website at:   www.ProAxsis.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEELFFBBLFFBV

(END) Dow Jones Newswires

October 16, 2020 02:00 ET (06:00 GMT)

1 Year Netscientific Chart

1 Year Netscientific Chart

1 Month Netscientific Chart

1 Month Netscientific Chart
ADVFN Advertorial
Your Recent History
LSE
NSCI
Netscienti..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201022 12:35:53